ARTICLE | Clinical News
Recombinant a-L-iduronidase: Phase I
January 26, 1998 8:00 AM UTC
Glyko Biomedical Ltd. (GLYK), Novato, Calif. Product: Recombinant a-L-iduronidase Indication: Repair deficiency of Hurler syndrome Status: BioMarin Pharmaceutical Inc., which is 40 percent owned by G...